Array Appoints Patricia Henahan CFO
This article was originally published in Scrip
Boulder, Colorado-based Array Biopharma, a company focused on developing targeted small molecule drugs to treat cancer, has named Patricia Henahan chief financial officer (CFO). Before joining Array, Henahan was vice-president of finance at Hospira. Prior to this, she was CFO of AstraZeneca plc and has also held other various leadership roles at companies such as Eli Lilly and MedImmune.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.